Lacey Lemoine
Family · Alexandria, LANPI 1730707837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 1,464 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,464 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Neurocrine Biosciences, Inc.$2K
- UCB, Inc.$1K
- Amgen$1K
- Biogen$1K
- AstraZeneca$1K
- plus $13K from 52 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$930%
- Food & beverage$24,41498%
- Education$1991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,006 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 13 | $926,186 |
| SolirisEculizumab | 11 | $300,411 |
| IngrezzaValbenazine Tosylate | 30 | $244,168 |
| AubagioTeriflunomide | 24 | $222,501 |
| Kesimpta PenOfatumumab | 18 | $173,691 |
| Nurtec OdtRimegepant Sulfate | 82 | $161,464 |
| AustedoDeutetrabenazine | 14 | $102,500 |
| NuplazidPimavanserin Tartrate | 22 | $100,241 |
| QuliptaAtogepant | 53 | $63,410 |
| RytaryCarbidopa/Levodopa | 39 | $48,005 |
| UbrelvyUbrogepant | 33 | $46,759 |
| FycompaPerampanel | 35 | $43,040 |
| AptiomEslicarbazepine Acetate | 20 | $27,717 |
| XcopriCenobamate | 17 | $22,597 |
| KeppraLevetiracetam | 20 | $22,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris, Soliris | $1,311 | $1,226,59724 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,951 | $244,16830 claims |
| SanofiAubagio | $859 | $222,50124 claims |
| PfizerNurtec Odt | $728 | $161,46482 claims |
| AbbVieQulipta, Ubrelvy | $4,593 | $110,16986 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $154 | $102,50014 claims |
| Acadia Pharmaceuticals IncNuplazid | $466 | $100,24122 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $345 | $50,76087 claims |
| Eisai Inc.Fycompa, Dayvigo | $581 | $46,56946 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $32 | $27,71720 claims |
| SK Life Science, Inc.Xcopri | $968 | $22,59717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Alexandria
- Kimberly RaoAlexandria$84K
- Kimberly LabordeAlexandria$14K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.